I[n]{.smallcaps}eukaryotic cells, the unique identity of each membrane-bounded compartment is maintained by proper targeting and sorting of proteins. Within the secretory pathway, proteins and lipids move between compartments via vesicular transport ([@B46]). The specificity of this transport is regulated by selective packaging of content into vesicles, specific interaction of receptors on transport vesicles and target membranes, and selective membrane and protein retrieval and retention ([@B57]; [@B60]). In recent years, many components of the vesicular transport machinery, as well as regulatory molecules that confer specificity and directionality, have been identified and characterized.

The endosomal membrane system is a branch of the secretory pathway in which biosynthetic traffic intersects with endocytic traffic from the cell surface. Among the best-characterized processes in the endosomal/lysosomal pathway is the mechanism by which newly synthesized soluble hydrolases are delivered to the lysosome ([@B30]). In mammalian cells, proteins tagged with a mannose-6-phosphate sorting signal interact with mannose-6-phosphate receptors in the Golgi complex. The interaction leads to sorting away from secreted proteins and delivery to endosomes ([@B30]). In yeast, \>40 *VPS* genes encode proteins required for proper trafficking from the Golgi to the vacuole ([@B56]; [@B54]). The hallmark of *vps* mutants is abnormal delivery of vacuolar enzyme precursors, such as procarboxypeptidase Y, to the cell surface. As in mammalian cells, there is a sorting receptor, encoded by *VPS10*, whose recognition of a signal within carboxypeptidase Y (CPY)^1^ and other soluble hydrolases in the late Golgi compartment is required for proper delivery via endosomes to the vacuole ([@B73]; [@B35]; [@B10]). Vps10 and other late Golgi membrane proteins, e.g., Kex2, are thought to maintain their localization by cycling between the Golgi and endosome compartments in a manner controlled by signals in their cytoplasmic tails ([@B9]; [@B76]; [@B43]; [@B6]; [@B10]).

Targeting of lysosomal membrane proteins in mammalian cells is mediated by sorting motifs in the cytoplasmic tails ([@B24]). In yeast, by contrast, the question of whether delivery of vacuolar membrane proteins is mediated by sorting signals or whether vacuolar membrane protein traffic occurs by default remains unresolved ([@B69]; [@B42]). Our understanding of the biosynthetic pathway to the vacuole in yeast is complicated by multiple vesicle-- mediated routes (Piper, R., N. Bryant, and T.H. Stevens. 1996. *Mol. Biol. Cell.* 7:322a; [@B11]). Furthermore, it has recently been shown that some misfolded proteins are targeted to the vacuole via a biosynthetic route ([@B23]).

The general organization of the endocytic pathway is well established ([@B20]). Extracellular molecules and plasma membrane proteins are internalized and move to early endosomes, where some proteins may recycle back to the cell surface. Other internalized proteins move to late endosomes and lysosomes, where they may be degraded. The set of proteins implicated in endosomal/vacuolar transport is expanding ([@B20]). In addition, there is growing evidence that phosphoinositides play a critical role in regulating membrane traffic in the endosomal/vacuolar pathway ([@B14]). Nevertheless, it is still unclear what the precise mechanisms by which these molecules regulate transport through the endocytic pathway are, and controversy remains about the structure and organization of endosomes. Further complexity is provided by evidence for more than one endocytic pathway ([@B59]).

The approach we have taken to investigate molecular aspects of the endosomal/lysosomal pathway is to study a targeting-defective mutant in *PMA1*, encoding the plasma membrane ATPase. In wild-type cells, newly synthesized Pma1 is delivered to the plasma membrane via the secretory pathway ([@B8]). Upon arrival at the cell surface, Pma1 is quite stable with a half-life of ∼11 h ([@B4]). By contrast, targeting-defective mutant Pma1 is delivered to the vacuole for degradation without ever arriving at the plasma membrane ([@B7]). The mutant is temperature sensitive; the cells undergo growth arrest after shifting to the restrictive temperature as the essential ATPase activity preexisting at the cell surface becomes limiting ([@B7]). At present, the molecular basis for transport of mutant Pma1 to the vacuolar pathway is not understood. However, we found previously that mutant Pma1 is enzymatically active, and multicopy suppression of temperature-sensitive *pma1* occurs by rerouting mutant Pma1 to the plasma membrane ([@B7]). This observation suggested that it might be possible to isolate mutants that affect membrane traffic in the endosomal pathway by selecting suppressors of temperature-sensitive growth of *pma1.*

In this paper, we report isolation of 16 suppressor of *pma1* (*sop*) mutants that divert newly synthesized mutant Pma1 from delivery to the vacuole. Identification of the corresponding *SOP* genes reveals a group identical to a subset of *VPS* genes required for delivery to the vacuole and also reveals additional novel regulators of protein traffic. Strikingly, the *sop* mutants display defects in traffic from endosome to vacuole and/or between endosome and Golgi. Our data indicate that mutant Pma1 is delivered to the cell surface as a consequence of disparate defects in the endosomal system. These findings have important implications for protein trafficking in the endosomal pathway.

Materials and Methods
=====================

Strains and Media
-----------------

Standard yeast media and genetic manipulations were as described ([@B64]). Strains used in this study are listed in Table [I](#TI){ref-type="table"}. All strains are isogenic with L3852. *sop pma1-7* mutants (WLY strains in Table [I](#TI){ref-type="table"}) were generated by transformation of ACY7 with a mutagenized genomic library ([@B5]). *PMA1 sop* strains used in this study were made by crossing *sop pma1* mutants with L5488. A collection of 42 *vps* mutants was obtained from Bruce Horazdovsky (University of Texas, Dallas, TX) for complementation analysis with CPY-secreting *sop* mutants. ACY33 (*vps27-Δ1::LEU2*) was generated by transformation of L3852 with pKJH2 ([@B49]). ACY70 (*vps27-123*) was generated by pop-in, pop-out gene replacement in ACY7 using pRCP20 ([@B49]). *vps1::LEU2* (ACX58-3C) was generated by transformation of ACX 28 (Mat α/**a** *his3Δ2*/*his3Δ2 lys2Δ201*/*lys2Δ201 leu2-3,112*/*leu2-3,112 ura3-52*/*ura3-52 ade2*/*ade2 pma1-7*/*PMA1*) with the disruption construct pCKR3A ([@B58]). pKJH2, pRCP20, and pCKR3A were obtained from Tom Stevens (University of Oregon, Eugene, OR). Yeast transformations were performed by the lithium acetate method ([@B18]).

Genetic Selection
-----------------

*pma1-7* (ACY7) cells were transformed with each of 14 independent pools of a mutagenized genomic library containing random *lacZ* and *LEU2* insertions ([@B5]). Leu^+^ transformants (∼139,000) were plated at 37°C to select for suppressors of temperature-sensitive growth. 63 strains that grew at 37°C were crossed with WLX2-2A, and the diploid was subjected to tetrad analysis to determine whether suppression of *pma1^ts^* was linked to a single *LEU2* insertion. Sequence analysis of genomic DNA adjacent to the insertion was undertaken as described ([@B5]). Briefly, *sop* cells were transformed with PvuI-cleaved YIp5. Genomic DNA was prepared from transformants, cleaved with NsiI, and ligated. Sequencing of plasmid DNA was carried out using the dideoxy chain termination method using Sequenase (United States Biochemical, Cleveland, OH). Sequences were analyzed using BLAST ([@B1]).

Indirect Immunofluorescence and FM 4-64 Endocytosis
---------------------------------------------------

Immunofluorescent localization of Pma1 was done essentially as described ([@B55]). Briefly, mid-log cultures were harvested, resuspended in 0.1 M K phosphate, pH 6.5, with 4.4% formaldehyde, and incubated for 2 h at room temperature. Cells were spheroplasted with oxalyticase (Enzogenetics, Corvallis, OR). For Pma1 staining, cells were permeabilized with methanol and acetone before incubation overnight with affinity-purified rabbit anti-Pma1 antibody. For double staining of Pma1 and vacuolar H^+^-ATPase, cells were permeabilized with SDS, as described ([@B53]), followed by incubation with rabbit anti-Pma1 and mouse monoclonal antibody against the 60-kD subunit of the V-ATPase (Molecular Probes, Inc., Eugene, OR). Primary antibody staining was visualized with Cy3- and DTAF-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA).

For FM 4-64 internalization studies, cells were grown to mid-log phase in YPD. After resuspension in fresh YPD at 20 OD~600~/ml, 20 μM FM 4-64 was added for 5 min at 30°C. Cells were washed, and incubation continued at 30°C for 1 h. FM 4-64 fluorescence was observed with rhodamine fluorescence filter sets, as described ([@B72]).

Western Blot and Invertase Assay
--------------------------------

Steady-state levels of Pma1, CPY, and Kex2 were analyzed in cell lysates, prepared from mid-log cultures by vortexing with glass beads, as described previously ([@B8]). Samples were normalized to lysate protein using the Bradford assay (Bio-Rad Laboratories, Hercules, CA). After separation by SDS-PAGE, samples were transferred to nitrocellulose for Western blot with rabbit antibodies against Pma1, CPY, or Kex2, and ^125^I--protein A (Amersham Corp., Arlington Heights, IL).

To study trafficking of mutant invertase--Wbp1 fusion protein, cells were transformed with pEG1-QK ([@B17]). Invertase activity was measured as described previously ([@B19]; [@B27]). Briefly, mid-log cultures grown in synthetic complete medium without uracil were harvested, washed with 10 mM sodium azide, and resuspended in 0.1 M sodium acetate, pH 5.1. Samples were divided for assaying cell surface and intracellular invertase activity. Whole cells were used to assay cell surface activity. Total intracellular invertase was measured in samples brought to 1% Triton X-100 and lysed by freeze-thaw with liquid N~2~. All strains studied are Suc2^+^ and were grown in the presence of 2% glucose. Endogenous invertase activity was measured in several random *sop* mutants (*bsd2*, *pep11*, and *vps13*) bearing vector alone. Endogenous invertase activity, representing ∼13% activity seen in the presence of pEG1-QK, was subtracted from activity measured in the presence of the plasmid.

CPY and α Factor Secretion
--------------------------

CPY secretion from cells was detected as described ([@B53]). Strains were replica-plated onto a nitrocellulose filter (Schleicher and Schuell, Dassel, Germany) and allowed to grow at 30°C. After ∼24 h, the filter was washed with water to remove adsorbed cells. CPY secreted onto the filter was detected by Western blot using rabbit polyclonal anti-CPY antibody. Immune complexes were visualized by chemiluminescence detection reagents (ECL Western blotting detection system; Amersham Corp.).

Secretion of α factor was detected essentially as described ([@B77]). Cells were grown to mid-log phase in synthetic complete medium without methionine. Cells were harvested and resuspended at 0.8 OD~600~/ml in fresh medium with 1 mg/ml BSA. Expre^35^S^35^S (0.5 mCi) (New England Nuclear, Boston, MA) was added, and incubation continued for 50 min at room temperature. Medium was separated from cells by centrifugation at 19,500 *g* for 5 min. SDS was added to the medium to 1%, and samples were boiled. Secreted α factor was immunoprecipitated with anti--α factor antibody and analyzed by SDS-PAGE (15% gels) and autoradiography after treatment of gels with Amplify (Amersham Corp.).

Bioassay for α factor secretion was done as described ([@B68]). Patches of *MATα* cells were replica-plated onto a thin lawn of *MAT**a** bar1* cells (LM23-3az; \[Marsh, 1992\]) on synthetic complete medium. After 1--2 d at 30°C, halos surrounding patches of α cells were scored.

Results
=======

Vacuolar Delivery of Mutant Pma1 via an Endosomal Intermediate
--------------------------------------------------------------

To show that mutant Pma1 is delivered to the vacuole via an endosomal intermediate, indirect immunofluorescence was used to localize Pma1, and a marker of the vacuolar membrane, the 60-kD subunit of the vacuolar H^+^-ATPase. Fig. [1](#F1){ref-type="fig"} shows that in *pma1-7* cells, mutant Pma1 appears coincident with vacuoles, visualized by V-ATPase staining, and as indentations of the cell surface by Nomarski optics (*upper panel*). Mutant Pma1 is also seen frequently as one or two spots adjacent to, but distinct from, the vacuole (*arrowheads*). These spots have a striking similarity to an exaggerated endosomal or prevacuolar compartment that appears adjacent to the vacuole in a subset of *vps* mutants, categorized as class E *vps* mutants ([@B50]; [@B12]; [@B49]). To obtain further evidence for mutant Pma1 transit through an endosomal intermediate, a temperature-sensitive allele of *vps27*, a class E *vps* mutant, was introduced into *pma1-7* cells. Previous work has shown that proteins from both biosynthetic and endocytic pathways are rapidly accumulated in a prevacuolar or endosomal compartment upon shifting *vps27^ts^* to 37°C ([@B49]). Mutant Pma1 is seen predominantly in this prevacuolar compartment when *pma1-7 vps27^ts^* cells are shifted to 37°C for 1 h (Fig. [1](#F1){ref-type="fig"}, *lower panel*). In these cells, the 60-kD V-ATPase subunit is similarly accumulated in the prevacuolar compartment, in agreement with previous observations ([@B50]). These data suggest that mutant Pma1 traverses an endosomal compartment en route to the vacuole.

Rerouting of Targeting-defective Pma1 to the Cell Surface in sop Mutants
------------------------------------------------------------------------

To select mutants that suppress temperature-sensitive growth of *pma1-7*, cells were transformed with a mutagenized genomic library containing random insertions of *lacZ* and *LEU2* ([@B5]). *sop pma1-7* mutants that grew at 37°C were selected. Tetrad analysis of *sop pma1* × *pma1* diploids revealed that growth at 37°C of 53/63 *sop* mutants analyzed segregated 2:2, indicating these mutations represent single genetic loci. Of these, suppression of temperature-sensitive growth was linked to the *LEU2* insertion in 36 strains. All *sop pma1* mutants grow at both 30 and 37°C, while *pma1-7* cells grow at 30°C but cannot grow at 37°C. In Fig. [2](#F2){ref-type="fig"} *A*, growth of some representative *sop pma1* mutants is shown along with *PMA1* and *pma1-7* cells. *sop* selection resulted in identification of 16 independent genes.

In *pma1-7* cells, steady-state Pma1 protein is reduced because, even at the permissive temperature, a fraction of newly synthesized Pma1 is delivered to the vacuole; stabilization of mutant Pma1 protein reflects escape from degradation in the vacuole ([@B7]). To determine whether mutant Pma1 protein is stabilized in *sop* mutants, steady-state Pma1 protein was measured by Western blot in *PMA1*, *pma1-7*, and the sixteen *sop pma1-7* strains (Fig. [2](#F2){ref-type="fig"} *B*). Fig. [2](#F2){ref-type="fig"} *B* shows mutant Pma1 is increased to differing degrees in *sop* mutants (compare with *pma1-7*; Fig. [2](#F2){ref-type="fig"} *B*, *arrow*).

Growth arrest of *pma1-7* at 37°C cannot be prevented merely by inhibiting vacuolar proteolytic activity (upon disruption of *PEP4*, encoding proteinase A \[[@B28]\]), but requires that an increased fraction of Pma1 arrives at the cell surface ([@B7]). Therefore, suppression of growth arrest and Pma1 stabilization by *sop* mutants suggests rerouting to the plasma membrane. To confirm this idea, localization of mutant Pma1 was examined by indirect immunofluorescence in wild-type, *pma1-7*, and *sop pma1* cells. In wild-type cells, Pma1 staining is seen over the surface and around the cell perimeter, characteristic of plasma membrane localization (Fig. [3](#F3){ref-type="fig"}, *upper panel*). In *pma1-7* cells, mutant Pma1 staining appears coincident with vacuoles and also as perivacuolar spots, reflecting mislocalization to the endosomal/vacuolar pathway. In representative *sop pma1* cells, intracellular staining of mutant Pma1 largely disappears; rim staining is more apparent, indicating a redistribution of Pma1 to the plasma membrane (Fig. [3](#F3){ref-type="fig"}, *lower three panels*).

A Subset of sop Mutants Are vps Mutants
---------------------------------------

The identity of the 16 disrupted *sop* genes was determined by cloning and sequencing of genomic DNA immediately adjacent to the insertion ([@B5]). Database searches revealed that several *sop* mutants represent insertions in previously identified genes. Two of these are *BSD2*, previously isolated as a mutant suppressor of superoxide dismutase deletion ([@B32]), and *ALG8*, encoding a potential glucosyltransferase ([@B71]). Both proteins are localized to the ER, although the mechanism of suppression of *pma1^ts^* is unclear at present. Five other *sop* mutants are identical with *vps* mutants defective in vacuolar protein sorting, supporting the idea that a major mechanism of *pma1^ts^* suppression is by changing protein traffic. We found *sop* mutants identical with *pep11* ([@B29]), *mvp1* ([@B15]), *vps35* ([@B47]), *vps27* ([@B49]), and *vps8.* Although *pep11* was originally isolated as a mutant with reduced vacuolar protease activity ([@B29]), we find that it is defective for vacuolar protein sorting and secretes CPY (Fig. [4](#F4){ref-type="fig"} *A*).

CPY secretion assay was performed on the 16 *sop* mutants to determine whether we had isolated additional *vps* mutants whose DNA sequences were not in the database (Fig. [4](#F4){ref-type="fig"} *A*). In this way, we discovered that three additional *sop* mutants secrete CPY. By complementation of these three mutants with a collection of 42 *vps* mutants (obtained from B. Horazdovsky), we determined that our selection had resulted in identification of *VPS13*, *VPS36*, and *VPS38*, which had not been previously cloned and sequenced. Table [II](#TII){ref-type="table"} lists the database accession numbers for these three as well as some of the other *SOP* genes. The predicted protein sequences of *VPS13*, *VPS36*, and *VPS38* were then analyzed by BLAST searches, revealing novel proteins of 3144, 566, and 439 amino acids, respectively. No similarity was detected between these proteins and other protein sequences in the database. Hydropathy analysis showed that the three proteins have no obvious amino-terminal signal sequence or membrane-spanning domains. Analysis by BLAST and COILS2.1 ([@B33]) indicated that a region of Vps38 has some probability to form a coiled coil structure (not shown).

Previous work classifying *vps* mutants on the basis of vacuolar morphology is of importance to understanding the significance of identifying a subset of *vps* mutants as suppressors of *pma1^ts^* ([@B50]). Most of the *sop*/*vps* mutants fall into class A (*mvp1*, *pep11*, *vps35*, *vps13*, *vps38*, and *vps8*), which have vacuolar morphology similar to wild-type cells. In addition, two mutants, *vps27* and *vps36*, fall into class E, in which a prevacuolar compartment or late endosome accumulates ([@B50]; [@B49]; [@B52]).

In agreement with increased CPY secretion from *vps*/ *sop* mutants (Fig. [4](#F4){ref-type="fig"} *A*), cell-associated mature CPY in most of these cells is decreased by comparison with wild-type and *pma1-7* cells (Fig. [4](#F4){ref-type="fig"} *B*). Mature CPY is the predominant form found in wild-type and *pma1-7* cells. More mature CPY is seen in lysates from the class E mutants *vps27* and *vps36*, consistent with accumulation and processing of newly synthesized CPY in the proteolytically active prevacuolar compartment ([@B6]; [@B49]).

Several sop Mutants Increase Surface Expression of a Vacuole-directed Membrane Marker
-------------------------------------------------------------------------------------

*vps*/*sop* mutants cause diversion of CPY and mutant Pma1 to the cell surface, suggesting a general role for these genes in regulating traffic of vacuole-bound proteins. We wanted to test whether these and other *sop* mutants can divert a second vacuole-directed membrane protein to the cell surface. To do this, we used a chimeric membrane protein that was shown previously to travel to the vacuole without arrival at the plasma membrane ([@B17]). The construct is a fusion of invertase with the transmembrane domain and cytoplasmic tail of Wbp1, an ER membrane protein, with a Q-K substitution in the dilysine retrieval motif. Cells were transformed with a centromeric plasmid bearing the chimeric construct. The presence of the fusion protein at the plasma membrane was quantitated by assaying surface invertase activity in intact cells in comparison to total invertase activity in permeabilized cells. Expression of the chimera is high since it is regulated by the *PRC1* (encoding CPY) promoter ([@B17]).

Table [III](#TIII){ref-type="table"} shows that cell surface expression of the invertase--Wbp1--Q-K chimera is increased in all *vps*/*sop* mutants. Highest cell surface expression (\>40% of total) is seen in *vps8*, and cell surface expression in the other *vps*/ *sop* mutants ranges from 20--30% of total. Therefore, this group of *sop*/*vps* mutants causes rerouting of two membrane proteins from the vacuole to the plasma membrane. By contrast, non-*vps sop* mutants increase cell surface mutant Pma1 (Fig. [2](#F2){ref-type="fig"}) but do not significantly increase plasma membrane expression of the chimeric membrane marker.

Endosome-to-Vacuole Traffic Is Delayed in Several vps/sop Mutants
-----------------------------------------------------------------

Previous characterization of *vps27*, a class E *vps* mutant, suggests a model for suppression of *pma1^ts^*. *vps27* is characterized by delayed traffic from the endosome to the vacuole as well as from the endosome back to the Golgi ([@B49]); this phenotype appears to be a general characteristic of the class ([@B12]; [@B6]). The finding that two class E *vps* mutants, *vps27* and *vps36*, suppress *pma1^ts^* suggests cell surface delivery of mutant Pma1 may occur as a consequence of a block or delay in endosome-to-vacuole and/or endosome-to-Golgi traffic. To confirm that the efficiency of delivery from endosome to vacuole is reduced in *vps36*, we examined the endocytic pathway by following internalization of the fluorescent lipophilic styryl dye FM 4-64. FM 4-64 serves as a marker for bulk plasma membrane internalization; transport of the endocytic tracer from the cell surface to the vacuolar membrane occurs in a time-, temperature-, and energy-dependent manner ([@B72]). Cells were labeled with FM 4-64 for 5 min. The cells were then washed, and incubation continued for 1 h in fresh medium. Immediately after staining, internalized FM 4-64 is seen as cytoplasmic punctate staining in wild-type as well as *vps36* cells (not shown and Vida and Emr \[1995\]). Subsequently, cytoplasmic punctate staining in wild-type cells disappears concomitant with appearance of staining of vacuolar membrane. By 60 min after labeling, staining is seen predominantly at the vacuolar membrane in wild-type cells (Fig. [5](#F5){ref-type="fig"}). At this time in *vps36* cells, there is some FM 4-64 dye at the vacuolar membrane; however, dye also accumulates as a large bright spot next to the vacuole (Fig. [5](#F5){ref-type="fig"}). This staining is similar to that seen in the endosomal/prevacuolar compartment of *vps27* cells ([@B72]).

Using the dye uptake assay, we examined the other *sop* mutants. While none are defective in internalization of FM 4-64 (not shown), a subset of *sop* mutants displays defects in transport to the vacuole after internalization. Strikingly, we observed that FM 4-64 stains the vacuolar membrane by 1 h of internalization in *vps38* and *vps13* cells, but it is also accumulated in an endocytic intermediate compartment, seen as a bright spot next to the vacuole. The compartment is similar, although smaller than the prevacuolar compartment accumulated in class E *vps* cells. Thus, there is a delay in endocytic delivery to the vacuole in *vps38* and *vps13.* Moreover, perturbation of endocytic traffic was also observed in *vps8* (Fig. [5](#F5){ref-type="fig"}). By contrast with prevacuolar accumulation, a fraction of FM 4-64 accumulates as punctate cytoplasmic staining in *vps8*; this cytoplasmic accumulation fails to advance in the endocytic pathway, even 60 min after internalization. Thus, distinct endocytic defects are apparent among this subset of *sop* mutants.

Several sop Mutants Display Defective Pro--α factor Processing
--------------------------------------------------------------

Since endosome-to-vacuole traffic appears perturbed in a subset of *sop* mutants, we tested whether other endosome-mediated traffic pathways are also affected. It has been established that retention of membrane proteins in the late Golgi, i.e., Kex2, Kex1, and dipeptidyl aminopeptidase A is mediated by signals in their cytoplasmic domains that dictate recycling between Golgi and endosome compartments ([@B9]; [@B76]; [@B43]). Mutations in the protein transport machinery affecting exit from the Golgi and/or retrieval from the endosome result in mislocalization of late Golgi membrane proteins ([@B63]; [@B77]; [@B6]). One consequence of such mislocalization is a maturation defect for α factor precursor ([@B16]; [@B48]). Therefore, we assayed for production of biologically active α factor in *sop* cells. *MATα* cells were replica-plated onto a lawn of *MAT**a** bar1* cells which undergo growth arrest in response to the concentration of mature α factor secreted from each *MATα* cell. Wild-type *MATα* cells are surrounded by a large halo of growth inhibition (Fig. [6](#F6){ref-type="fig"} *A*). Cells deleted of *KEX2*, required for proteolytic processing of pro--α factor ([@B16]; [@B48]), produce no halo of growth inhibition. Most of the *vps*/*sop* mutants are surrounded by halos that are smaller to varying degrees than that of wild-type cells, indicating diminished secretion of mature, biologically active α factor. The smallest halos were observed surrounding *vps8* and *vps36.* Of the *vps*/*sop* subset, only *vps13* and *vps38* cells produce halos of growth inhibition comparable with wild-type cells. Halos surrounding *sop1-6* mutants are also comparable to that of wild-type cells.

One of the first steps in proteolytic processing of pro--α factor is Kex2-mediated removal of the pro-peptide ([@B16]; [@B48]). To determine whether unprocessed pro--α factor is secreted by *MATα sop* mutants, cells were radiolabeled with \[^35^S\]cysteine and \[^35^S\]methionine. α Factor--containing forms were then immunoprecipitated from the medium for analysis by SDS-PAGE and fluorography. Fig. [6](#F6){ref-type="fig"} *B* shows that α factor secreted by wild-type *MATα* cells is exclusively the processed, mature 3.5-kDa form (*lower arrow*). By contrast, several *sop* mutants secrete precursor α factor of ∼125-kD in addition to the processed form (Fig. [6](#F6){ref-type="fig"} *B*), indicating defective proteolytic processing by Kex2p. Strikingly, secretion of pro--α factor was detected in two non-*vps sop* mutants, *sop2* and *sop6* (Fig. [6](#F6){ref-type="fig"} *B*). Most of the *vps*/*sop* mutants also secrete unprocessed α factor, although secretion of pro--α factor is low from *vps8*, *vps13*, and *vps38. vps36* cells secrete the highest fraction of pro--α factor, consistent with production of a small halo (Fig. [6](#F6){ref-type="fig"} *A*), and an approximately sixfold decrease in mating efficiency by comparison with wild-type cells (not shown).

Steady-State Kex2 Levels in sop Mutants
---------------------------------------

Kex2p mislocalization has previously been observed in class E mutants ([@B6]). Since the prevacuolar compartment of class E mutants contains proteolytic activity ([@B6]; [@B49]), defective recycling between late Golgi and endosome results in failure of Kex2 to escape from *PEP4*-dependent degradation in the prevacuolar compartment. Consequently, there is a reduction in steady-state Kex2p levels. To examine whether degradation of Kex2 occurs in *sop* mutants, steady-state levels of Kex2 were measured by Western blot. As expected, Kex2 levels are reduced in the class E mutants *vps27* and *vps36* as compared with that of wild-type cells (Fig. [7](#F7){ref-type="fig"}, *arrow*). Strikingly, Kex2 levels are also significantly decreased in *mvp1*, *pep11*, and *vps35* cells, as well as the non-*vps sop* mutants, *sop2* and *sop6* (Fig. [7](#F7){ref-type="fig"}, compare with Kex2 in wild-type cells). Steady-state Kex2 levels are similar in *sop* and wild-type cells upon deletion of *PEP4* (not shown), indicating that Fig. [7](#F7){ref-type="fig"} reflects differences in Kex2 degradation. A comparison of the *sop* mutants reveals that, in general, mutants with less Kex2 secrete more pro--α factor, and less pro--α factor secretion is seen in mutants with more Kex2 (compare Fig. [7](#F7){ref-type="fig"} with Fig. [6](#F6){ref-type="fig"} *B*). Among the class A *vps*/*sop* mutants, loss of Kex2 is not observed in mutants that have endosome-to-vacuole traffic defects (*vps13*, *vps38*, and *vps8*; Fig. [5](#F5){ref-type="fig"}). Intriguingly, in *vps8* there is no reduction in steady-state Kex2 levels even though there is a severe defect in production of biologically active α factor (Fig. [6](#F6){ref-type="fig"} *A*).

SOP2 Encodes a Homologue of Synaptojanin, a Member of the Inositol 5-Phosphatase Family
---------------------------------------------------------------------------------------

Secretion of pro--α factor as well as reduced steady-state Kex2 in *sop2* and *sop6* mutants suggests defective traffic between Golgi and endosome. Molecular characterization of the non-*VPS SOP* genes is in progress. However, analysis of the DNA sequence of *SOP2* revealed that the open reading frame of 3,323 nucleotides predicts a 1,107-amino acid polypeptide. Database search showed that Sop2 protein has high sequence similarity with synaptojanin, a nerve terminal protein with inositol 5-phosphatase (IP5P) activity ([@B37]). Synaptojanin is associated with dynamin and amphiphysin and has been proposed to play a role in synaptic vesicle endocytosis and recycling. Sop2 also has sequence similarity with two other yeast open reading frames (ORFs) in the database that were not picked up as suppressors of *pma1.* An alignment of these proteins is shown in Fig. [8](#F8){ref-type="fig"}. All four proteins contain two conserved motifs, GDXN(Y/F)R and P(S/A) W(C/T)DRI (Fig. [8](#F8){ref-type="fig"}, *asterisks*); these conserved residues have been proposed to function directly in catalysis for IP5Pases ([@B34]). Evidently, Sop2, like synaptojanin, plays a role in the endosomal pathway. Whether the two yeast homologues have overlapping function with Sop2 remains to be established.

Discussion
==========

Selection for sop Mutants
-------------------------

A targeting-defective *pma1* mutant has provided the means to select mutants affecting the endosomal/vacuolar pathway. Previously, multicopy suppression of targeting-defective *pma1* resulted in identification of *YPT7* (Chang, A., unpublished result), a member of the small GTPase family regulating endosome-to-vacuole traffic ([@B75]; [@B61]). In this report, we identify 16 *sop* mutants that permit *pma1-7* to grow at 37°C. While in principle it seems possible to suppress temperature-sensitive growth of *pma1-7* by altering the physiological demand for proton pumping at the cell surface, increased steady-state mutant Pma1 in *sop* mutants suggests inhibition of vacuolar degradation (Fig. [2](#F2){ref-type="fig"}). Therefore, allowing mutant Pma1 to escape vacuolar degradation by moving to the cell surface is a major mechanism of suppression (Fig. [3](#F3){ref-type="fig"}). Eight of the *sop* mutants are also defective for vacuolar delivery of CPY; these *vps* mutants have vacuolar morphologies belonging to class A and E ([@B50]). Five of the eight *VPS* genes were previously cloned and sequenced. *SOP* selection resulted in molecular identification and phenotypic characterization of three *VPS* genes, *VPS13*, *VPS38*, and *VPS36*, as well as six novel genes that regulate membrane traffic.

The subset of *sop* mutants that is defective for vacuolar protein sorting also reroutes a mutant Wbp1 fusion protein from the vacuole to the plasma membrane (Table [III](#TIII){ref-type="table"}). In *sop* cells, mutant Pma1 delivered to the plasma membrane appears to remain stable at the surface (Fig. [3](#F3){ref-type="fig"}). (By contrast, when an endogenous vacuolar membrane protein is diverted to the plasma membrane, it quickly undergoes endocytosis and moves to the vacuole \[[@B44]\].) It remains unknown, however, whether wild-type Pma1 localization at the plasma membrane is maintained by cycles of endocytosis and recycling back to the cell surface.

Endosome-to-Vacuole Traffic Defects in a Subset of vps/sop Mutants
------------------------------------------------------------------

Our results underscore the interplay between protein trafficking in the endocytic and biosynthetic pathways ([@B49]; Singer-Kruger, 1995). Previously, three *vps* mutants, *vps34*, *vps2*/*ren1*, and *vps21*/*ypt51*, have been identified that display dual defects in endocytic and biosynthetic traffic to the vacuole ([@B12]; [@B40]; Singer-Kruger, 1995). Because indirect immunofluorescence localization suggests mutant Pma1 traverses an endosomal compartment en route to the vacuole (Fig. [1](#F1){ref-type="fig"}), it was not unreasonable to hypothesize a defect in the endocytic pathway in some *sop* mutants. Indeed, the hypothesis is supported by endocytosis studies using FM 4-64 (Fig. [5](#F5){ref-type="fig"}). The class E mutant *vps36* accumulates dye in a prevacuolar/endosomal compartment, seen as a large spot adjacent to the vacuole, as described previously for *vps27* and other class E mutants ([@B72]; [@B52]). Interestingly, some class A *vps*/ *sop* mutants have characteristics in common with class E mutants. In *vps13* and *vps38*, we observed a delay in exit of FM 4-64 from an endocytic intermediate compartment(s). This compartment appears similar to the prevacuolar compartment of class E *vps* cells, although it does not appear to have substantial proteolytic activity (Fig. [7](#F7){ref-type="fig"}). Interestingly, *vps13* (*soi1*) was recently found in a screen for suppression of vacuolar mislocalization of a Kex2p mutant with a defective *trans*-Golgi localization signal ([@B51]). It is possible that in *vps13* cells, there is reduced vacuolar delivery of mutant Pma1 as well as the mutant Kex2 as a consequence of a delay in traffic from endosome to vacuole. Vacuolar delivery of FM 4-64 is also perturbed in *vps8* because a fraction of the dye accumulates in a novel endocytic intermediate that is seen as punctate cytoplasmic staining (see below).

Trafficking Defects between Endosome and Golgi in a Subset of sop Mutants
-------------------------------------------------------------------------

In class E *vps* mutants, retention of late Golgi membrane proteins is defective, and Kex2 undergoes *PEP4*-dependent degradation ([@B6]; [@B45]). In agreement with this observation, steady-state Kex2 levels are diminished in *vps27* and *vps36* cells by comparison with wild-type cells (Fig. [7](#F7){ref-type="fig"}). In several class A *vps*/*sop* cells (*mvp1*, *pep11*, and *vps35*; Fig. [7](#F7){ref-type="fig"}), steady-state Kex2p levels are also reduced, suggesting increased Kex2 degradation. Our findings are in contrast with a previous suggestion that class A *vps* mutants are defective specifically in the soluble protein-sorting apparatus ([@B50]). In *vps35* cells, secretion of unprocessed α factor and reduction of steady-state Kex2 levels (Figs. [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}) are consistent with reports that Vps35 acts at the endosome to direct recycling of other late Golgi membrane proteins from endosome to Golgi ([@B45]; [@B62]).

In *vps8* cells, secretion of pro--α factor is slight, and steady-state Kex2 levels are not significantly reduced (Figs. [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}). However, *vps8* cells produce a strikingly small halo (Fig. [6](#F6){ref-type="fig"} *A*), suggesting a defect in mature α factor production that is as yet undefined. One possible explanation for the small halo in *vps8* is suggested by the observation that FM 4-64 accumulates in a structure morphologically distinct from the class E prevacuolar compartment in *vps8* (Fig. [5](#F5){ref-type="fig"}). Moreover, two different populations of endosomes (early and late) have been identified in yeast, as in mammalian cells ([@B65]; [@B22]). It is possible that in *vps8* cells, there is a mild defect in Kex2 localization but more substantial mislocalization of the other *trans*-Golgi proteases, Kex1 and Ste13 (which are necessary for generating mature, biologically active α factor \[[@B16]\]).

Novel Non-vps sop Mutants
-------------------------

Selection of *pma1* suppressors has resulted in the isolation of six novel *sop* mutants. Of these, two *sop* mutants, *sop2* and sop6, secrete unprocessed α factor and also display diminished steady-state Kex2 levels (Figs. [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}). These data suggest that these non-*VPS SOP* gene products also participate in Kex2 trafficking and play a role in the endosomal/vacuolar pathway. While further work is necessary to dissect the molecular mechanism of the *SOP* gene products (see below), it is of interest to our understanding of endosomal protein trafficking that *SOP2* encodes a homologue of synaptojanin (Fig. [8](#F8){ref-type="fig"}). Synaptojanin, a nerve terminus protein, has been proposed to regulate synaptic vesicle endocytosis and recycling ([@B38]). Sop2 and synaptojanin are members of the family of IP5Pases that includes the protein defective in the oculocerebrorenal syndrome of Lowe ([@B3]). Sop2 has closest similarity to the type II IP5Pases, which dephosphorylate inositol polyphosphates as well as phosphatidylinositol(4,5)diphosphate and phosphatidylinositol(3,4,5)triphosphate ([@B14]; [@B34]). Enzymes involved in phosphatidylinositol metabolism have been found to regulate many aspects of cell physiology, including protein trafficking ([@B31]; [@B14]). In yeast, such enzymes have been implicated in protein transport through the Golgi ([@B67]) and from Golgi to vacuole ([@B70]). Our results suggest a role for Sop2 in trafficking between endosome and Golgi.

Models for Entry of Mutant Pma1 into the Endosomal/Vacuolar Pathway
-------------------------------------------------------------------

At present, the molecular basis for entry of mutant Pma1 into the endosomal/vacuolar pathway is not understood. One possible explanation for mislocalization of mutant Pma1 is that a novel post-ER quality control mechanism recognizes and directs mutant Pma1 to the endosomal/vacuolar pathway. In this regard, it is clear that some proteins continue to fold and assemble in post-ER compartments ([@B74]; [@B26]; [@B25]; [@B41]). Moreover, it has been observed that in both mammalian and yeast cells, some incompletely assembled or misfolded proteins are targeted for lysosomal degradation (without prior arrival at the plasma membrane) ([@B39]; [@B2]; [@B17]; [@B23]). Thus, the idea that quality control is not an exclusive ER function is receiving increasing consideration ([@B21]).

An alternative explanation for mutant Pma1 mislocalization is based on a proposal that, by contrast with mammalian cells, membrane protein traffic to the vacuole in yeast occurs by "default," i.e., membrane proteins without sorting signals are delivered to the vacuole ([@B69]; [@B42]). A corollary of this hypothesis is that plasma membrane proteins have targeting signals. According to this hypothesis, mutant Pma1 may have a defective plasma membrane targeting signal that results in its vacuolar delivery by default. (If there is a plasma membrane targeting machinery, we would not expect *SOP* genes to encode these components since *sop* mutants were generated by insertional mutagenesis.)

Models for SOP Action
---------------------

We have taken a first step towards understanding the mechanism of vacuolar delivery of mutant Pma1 by identifying *SOP* genes. Different trafficking defects seen in the *sop* mutants suggest diverse means by which mutant Pma1 moves to the cell surface. We suggest that the *sop* mutants fall into three classes depending on how vacuolar delivery of mutant Pma1 is inhibited. One possible mode of *sop* action is a direct one, in which a defect in the mechanism directing mutant Pma1 into endosome-bound vesicles at the Golgi results in transport of mutant Pma1 from Golgi to surface. For example, this class of *SOP* genes may encode constituents of a quality control mechanism that recognize mutant proteins at the Golgi. Indeed, *SOP3*, *SOP4*, and *SOP5* may fall into this class. *sop3*, *sop4*, and *sop5* mutants suppress *pma1* without affecting CPY delivery (Fig. [4](#F4){ref-type="fig"}), Kex2 recycling (Figs. [6](#F6){ref-type="fig"} *B* and *7*), or endocytic uptake of FM 4-64 (not shown). *SOP3*, *SOP4*, and *SOP5* encode predicted transmembrane proteins, and Sop3 and Sop5 have similarity to mammalian receptors (Luo, W., and A. Chang, unpublished result). These characteristics are consistent with a possible "receptor" function for these proteins.

Most of the *sop* mutants appear to fall into two additional classes that change traffic independently of the primary mislocalization event, resulting in cell surface delivery of mutant Pma1. Mutations in *SOP* genes of these two classes may affect traffic at either the Golgi or an endosome compartment. For example, loss of proteins required for formation of Golgi-to-endosome vesicles may slow exit from the Golgi, and mutant Pma1 may escape to the surface as a consequence. Mutants defective in endosome-to-Golgi recycling may similarly suppress *pma1* by slowing exit from the Golgi since proteins required for formation of Golgi-to-endosome vesicles have to recycle back. We have placed the *sop*/*vps* mutants *mvp1*, *pep11*, *vps35*, the class E mutants *vps27* and *vps36*, and *sop2* and *sop6* in this class because Kex2 trafficking between Golgi and endosome appears defective in these mutants (Fig. [7](#F7){ref-type="fig"}).

Diversion of mutant Pma1 to the cell surface after its arrival in an endosomal compartment is another mechanism of suppression. If there is a defect or delay in traffic from endosomes to the vacuole, it is possible that newly synthesized mutant Pma1 en route to the vacuole moves directly from the endosome to the plasma membrane. *vps13*, *vps38*, and *vps8* are candidates for this subclass; these *vps*/ *sop* mutants are defective in endosome-to-vacuole traffic (Fig. [5](#F5){ref-type="fig"}) but do not display severe trafficking defects between Golgi and endosome (Fig. [7](#F7){ref-type="fig"}). The class E *vps* mutants display defects in trafficking in both pathways. Further work is required to determine whether mutant Pma1 is diverted to the plasma membrane from the Golgi or after its entry into endosomes in *vps27* and *vps36* mutants. A previous report that there is an increase in the cell surface **a** factor receptor Ste3 in a class E *vps* mutant is consistent with endosome-to-plasma membrane trafficking ([@B12]). Although an endosome-to-surface traffic pathway has not been described formally in yeast, such a pathway has been established clearly in mammalian cells ([@B20]; [@B13]).

Disparate defects in the endosomal system in *sop* mutants suggest that protein traffic to the cell surface may occur via multiple mechanisms. Future studies to dissect the mechanisms of the *SOP* genes should aid in revealing novel means to deliver proteins to the cell surface, as well as further defining the endosomal system in molecular terms.
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CPY

:   carboxypeptidase

IP5P

:   inositol 5-phosphatase

ORF

:   open reading frame

*sop*

:   suppressor of *pma1.*

###### 

Yeast Strains Used in This Study

  Strains        Genotype                                                                           Source
  ----------- -- ------------------------------------------------------------------------------- -- ------------------------------------------------------
  L3852          *MATα his3Δ200 lys 2Δ201 leu2-3,112 ura3-52 ade2*                                  Fink lab collection, Whitehead Institute
  L5488          *MAT**a** lys2Δ201 leu2-3,112 ura3-52*                                             Fink lab collection, Whitehead Institute
  ACY7           *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7*                            [@B7]
  WLX2-2A        *MATα lys2Δ201 leu2-3,112 ura3-52 pma1-7*                                          This study
  WLY1           *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 bsd2-Δ1::LEU2*              This study
  WLY2           *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 vps13-Δ1::LEU2*             This study
  WLY4           *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 alg8::LEU2*                 This study
  WLY10          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 sop5::LEU2*                 This study
  WLY12          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 vps36-Δ1::LEU2*             This study
  WLY13          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 pep11::LEU2*                This study
  WLY16          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 vps8::LEU2*                 This study
  WLY19          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 sop6-Δ1::LEU2*              This study
  WLY22          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 sop2-Δ1::LEU2*              This study
  WLY25          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 vps27-Δ1::LEU2*             This study
  WLY29          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 sop4::LEU2*                 This study
  WLY33          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 sop3::LEU2*                 This study
  WLY37          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 mvp1-Δ1::LEU2*              This study
  WLY38          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 vps35-Δ1::LEU2*             This study
  WLY40          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 vps38-Δ1::LEU2*             This study
  WLY57          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 sop1::LEU2*                 This study
  ACX58-3C       *MATα his2Δ201 lys2Δ201 leu2-3,112 ura3-52 ade2 vps1Δ::LEU*                        This study
  WLX3-2A        *MATα lys2Δ201 leu2-3,112 ura3-52 ade2 sop2-Δ1::LEU2*                              This study
  WLX8-1B        *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 sop4::LEU2*                        This study
  WLX9-12C       *MATα lys2Δ201 leu2-3,112 ura3-52 sop3::LEU2*                                      This study
  WLX10-2A       *MATα lys2Δ201 leu2-3,112 ura3-52 sop5::LEU2*                                      This study
  WLX11-1C       *MATα lys2Δ201 leu2-3,112 ura3-52 sop6-Δ1::LEU2*                                   This study
  WLX12-7C       *MATα lys2Δ201 leu2-3,112 ura3-52 vps36-Δ1::LEU2*                                  This study
  WLX13-3B       *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 pep11::LEU2*                            This study
  WLX14-10A      *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 vps38-Δ1::LEU2*                    This study
  WLX15-4C       *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 vps13-Δ1::LEU2*                         This study
  WLX16-1A       *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 vps8::LEU2*                        This study
  WLX17-6D       *MATα lys2Δ201 leu2-3,112 ura3-52 mvp1-Δ1::LEU2*                                   This study
  WLX18-6D       *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 vps35-Δ1::LEU2*                         This study
  WLX19-3A       *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 sop1::LEU2*                             This study
  ACY33          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 vps27::LEU2*                       This study
  ACY70          *MATα his3Δ200 lys2Δ201 leu2-3,112 ura3-52 ade2 pma1-7 vps27-123(ts)*              This study
  BFY106-4D      *MATα his3-11,15 leu2-3,112 ura3-1 trp1-1 ade2-1^oc^ can1-100 kex2Δ2::HIS3-A*      Robert Fuller, University of Michigan, Ann Arbor, MI
  LM23-3az       *MAT**a** bar1 ura3 leu2 his4 trp1 met1 \[FUS1-lacZ::URA3\]*                       Marsh (1992)

 

![Indirect immunofluorescence localization of mutant Pma1 in a prevacuolar compartment. Localization of Pma1 and V-ATPase in *pma1-7* and *pma1-7 vps27^ts^* cells. Mid-log cultures were harvested, fixed, and spheroplasted. Cells were permeabilized with SDS before staining with rabbit anti-Pma1 and mouse monoclonal antibody against the 60-kD subunit of V-ATPase, followed by species-specific CY3- and DTAF-conjugated secondary antibodies. (*Upper panel*) Mutant Pma1 staining is coincident with V-ATPase staining at the vacuolar membrane in *pma1-7* cells at 30°C. In these cells, mutant Pma1 is also seen as spots distinct from the vacuole (*arrowheads*). Nomarski optics show vacuoles as indentations. (*Lower panel*) *pma1-7 vps27^ts^* cells were shifted to 37°C for 1 h. Both mutant Pma1 and the 60-kD V-ATPase subunit are accumulated in the prevacuolar compartment.](JCB.14552f1){#F1}

![Suppression of temperature-sensitive growth and stabilization of mutant Pma1 protein in *sop* mutants. (*A*) Growth at 30 and 37°C on plates (synthetic complete medium). *PMA1* (L5488) cells grow at 30 and 37°C, whereas *pma1-7* (ACY7) cells grow at 30°C but do not grow at 37°C. *sop*/*vps pma1* cells (WLY2, WLY12, WLY22, WLY 25, WLY33, WLY40) grow at 30 and 37°C. (*B*) Western blot showing steady-state levels of Pma1 protein. Lysate was prepared from *PMA1*, *pma1-7*, and *sop pma1-7* cells exponentially growing at 30°C. Samples were normalized to lysate protein. Pma1 protein was detected using anti-Pma1 antibody and ^125^I--protein A followed by autoradiography. Bar graph shows quantitation of Pma1 levels in wild-type and *sop pma1-7* mutants by densitometric scanning of the autoradiogram. Pma1 levels are normalized to that of *pma1-7* (*arrow*), set arbitrarily to 1.0. Western blot is representative of three to five independent measurements in which the standard deviation of the mean is on average 26%.](JCB.14552f2){#F2}

![Mutant Pma1 is rerouted to the cell surface in *sop* mutants as seen by indirect immunofluorescence. Cells exponentially growing at 30°C were fixed, permeabilized, and stained with rabbit anti-Pma1 antibody followed by CY3-conjugated secondary antibody. *PMA1* (L5488) cells show cell surface Pma1 localization (*top panel*) while *pma1-7* cells (ACY7) display striking intracellular staining (*second panel*). Suppressed *pma1-7* cells display a predominant plasma membrane distribution of mutant Pma1 (*lower three panels*). *sop pma1* strains shown are WLY2, WLY22, and WLY25.](JCB.14552f3){#F3}

![A subset of *sop* mutants is defective for vacuolar protein sorting. (*A*) Western blot detecting secretion of CPY. Cells were overlayed with nitrocellulose overnight. Secreted CPY adsorbed to the membrane was visualized with rabbit anti-CPY followed by horseradish peroxidase--conjugated secondary antibody and chemiluminescence detection reagents. *PMA1* (L5488) and *pma1-7* (ACY7) are shown as non--CPY-secreting controls. *vps1Δ* (ACX58-3C), which secretes the vast majority of newly synthesized pro-CPY ([@B50]), is included as a positive control. (*B*) Western blot showing intracellular CPY. Protein lysate was prepared from exponentially growing cells, as described in Methods. Samples were normalized to lysate protein. CPY was detected as described above. Strains assayed (left to right) are: ACY7, L3852, WLX17-6D, WLX13-3B, WLX18-6D, ACY33, WLX12-7C, WLX15-4C, WLX16-1A, and WLX14-10A. Mature CPY associated with *vps* cells is substantially decreased by comparison with *PMA1* and *pma1-7* cells.](JCB.14552f4){#F4}

###### 

Identification of New and vps Genes by sop Selection

  Gene             Insertion position                          Remarks/reference                                              Accession number
  ------------- -- ---------------------------------------- -- ----------------------------------------------------------- -- ---------------------------------------
  *VPS36* (2)      ND; 932/1700                                New gene  ID by complementation  566 amino acids               gb U20162_7.cds YLR417w
  *VPS13* (4)      3797; 7694; 8961; ND/9434                   New gene  ID by complementation  3144 amino acids  [@B51]      emb Z73145 YLL040c
  *VPS38* (2)      241; ND/1319                                New gene  ID by complementation  439 amino acids               gb U19103_2.cds YLR360w
  *VPS8* (1)       382/3531                                    1176 amino acids                                               gb U44026_1.cds YAL002w
  *PEP11* (1)      386/846                                     282 amino acids                                                SwissProt P38759 YHR012w
  *VPS35* (2)      2555; 249/2813                              [@B47]                                                         
  *MVP1* (2)       1417; 33/1535                               [@B15]                                                         
  *VPS27* (2)      84/1868                                     [@B49]                                                         
  *BSD2* (8)       88;87; 810; 44; 563; 677; −53; 122/966      [@B32]                                                         
  *ALG8* (1)       1192/1733                                   [@B71]                                                         
  *SOP2* (3)       1120;120; 669/3323                          New gene  1,107 amino acids  homology to synaptojanin          embX94335_26.cds  SC130kbXV; YOR3231w

The number of times each *sop* gene was selected out of 63 *sop* mutants picked is indicated in parentheses. Insertion site indicates the codon at which *lacZ* is inserted and the total number of codons in the gene. In some cases, insertion site information is not available (ND) because identification of the *sop* mutation was made by complementation only. DNA sequencing and database searching revealed the *sop* mutations that had been previously identified, cloned, and sequenced in other genetic screens. All other *sop* mutants are insertions within novel open reading frames. Complementation analysis of CYP-secreting *sop* mutants with a complete set of *vps* mutants led to identification of *vps13*, *vps36*, and *vps38*. Accession and locus designations are indicated for these vps. Molecular information on five non-*vps sop* mutants (*sop1*, *sop3-6*) is not presented here because further phenotypic characterization is in progress.  

###### 

Quantitation of Cell Surface Expression of a Vacuolar Membrane Marker in sop Mutants

  Strain              Percent activity at surface
  ---------------- -- -----------------------------
  *pma1-7*             9.7
  *sop1 pma1-7*       10.7
  *sop2 pma1-7*        7.6
  *sop3 pma1-7*       17.0
  *sop4 pma1-7*        6.8
  *sop5 pma1-7*        6.8
  *sop6 pma1-7*        8.5
  *mvp1 pma1-7*       20.0
  *pep11 pma1-7*      30.9
  *vps35 pma1-7*      33.1
  *vps27 pma1-7*      18.1
  *vps36 pma1-7*      29.3
  *vps13 pma1-7*      27.2
  *vps8 pma1-7*       41.7
  *vps38 pma1-7*      29.5
  *PMA1*               8.5
                      

*PMA1* (L3852), *pma1-7* (ACY7), and *sop pma1* cells (Table [I](#TI){ref-type="table"}) were transformed with pEG1-QK bearing a mutant *WBP1-SUC2* fusion ([@B17]) and assayed after growth to mid-log phase in synthetic complete medium minus uracil (2% glucose). Intracellular and cell surface invertase activity were measured by assaying detergent-permeabilized and intact cells, respectively ([@B27]). Invertase activity is expressed as nmol glucose released per min per OD~600~. Since all the strains are Suc2^+^, endogenous invertase activity (in the absence of the fusion protein) was subtracted from activity measured in the presence of pEG1-QK. Under the glucose-repressing conditions of the experiment (2% glucose), endogenous intracellular invertase activity represented an average of 13.3% of total activity (*n* = 39) measured in the presence of the fusion protein. Endogenous invertase activity was measured in *bsd2*, *vps36*, and *pep11* in the presence of vector alone; activity was similar in all strains. Cell surface invertase activity is expressed as a percent of total and represents the average of two to four independent experiments per strain. All measurements were performed in quadruplicate. A diagram of the Wbp1--invertase fusion with the Q-K substitution in the cytoplasmic carboxy terminus is drawn as described previously ([@B17]).  

![Visualization of endocytosis in *sop* mutants by FM 4-64 staining. Exponentially growing wild-type cells and *sop* mutants were stained with FM 4-64 for 5 min at 30°C, washed, and incubated in fresh YPD for 1 h before visualization and photography. Vacuolar membrane staining is seen in wild-type cells (L3852). In *vps36* (WLX12-7C), a class E *vps* mutant, FM 4-64 dye is accumulated in a prevacuolar compartment. A similar accumulation of dye as a spot near the vacuole is seen in *vps38* (WLX14-10A) and *vps13* (WLX15-4C). Bright punctate staining in the cytoplasm remains in *vps8* (WLX16-1A) after 1 h of chase.](JCB.14552f5){#F5}

![Production of biologically active α factor and secretion of unprocessed pro--α factor by *sop* mutants. (*A*) Secretion of biologically active mature α factor was detected by halo assay. Wild-type (L3852) and *sop* mutants were patched on plates with synthetic complete medium and allowed to grow overnight. The *MATα* strains were then replica-plated onto a lawn of *MAT**a** bar1* cells (LM23-3AZ; Table [I](#TI){ref-type="table"}). After 1--2 d, halos surrounding patches of α cells were scored. No halo is observed surrounding *kex2Δ* cells (BFY106-4D), which is included as a control. *sop* mutant strains are: WLX19-3A, WLX3-2A, WLX9-12C, WLX8-1B, WLX10-2A, WLX11-1C, WLX12-7C, WLX13-3B, WLX14-10A, WLX15-4C, WLX16-1A, WLX17-6D, WLX18-6D, and ACY33. (*B*) Secretion of pro--α factor by wild-type and *sop* cells. Exponentially growing cells (0.4 OD~600~/0.5 ml) were labeled at room temperature with Expre^35^S^35^S for 50 min. Culture medium was collected, adjusted to 1% SDS, and boiled. Secreted α factor was immunoprecipitated from the medium, and analyzed by SDS-PAGE (15% polyacrylamide gel) and fluorography. The lower arrowhead indicates mature α factor, a 3.5-kD peptide, and the upper arrowhead indicates precursor α factor with a molecular mass of ∼125 kD. Wild-type cells secrete mature α factor exclusively. A subset of *sop* cells secrete both unprocessed and mature α factor. Strains assayed are: WLX19-3A, WLX3-2A, WLX9-12C, WLX8-1B, WLX10-2A, WLX11-1C, L3852, WLX17-6D, WLX13-3B, WLX18-6D, ACY33, WLX12-7C, WLX15-4C, WLX16-1A, and WLX14-10A.](JCB.14552f6){#F6}

![Steady-state Kex2 levels in *sop* mutants. Western blot measuring steady-state level of Kex2p. Lysate (100 μg protein) from wild-type (L3852) and *sop* mutants (strains listed in Fig. [6](#F6){ref-type="fig"} *B* legend) was resolved by SDS-PAGE and transferred to nitrocellulose. Kex2p was detected by rabbit anti-Kex2 antibody followed by ^125^Iprotein A and autoradiography. Bar graph shows quantitation of Kex2 levels in *sop* mutants normalized to that of wild-type (*arrow*) by densitometric scanning of the autoradiogram. Measurements are representative of two to four experiments.](JCB.14552f7){#F7}

###### 

Sop2 is a member of the inositol 5-phosphatase family and a homologue of synaptojanin. Alignment of Sop2 with rat brain synaptojanin (gi1166575) and two yeast ORFs. OrfN2160 on chromosome XIV is available from GenBank/EMBL/DDBJ under accession number [Z50161](Z50161). Orf [P40559](P40559), a hypothetical 108.4-kD protein on chromosome IX, is in the SWISS-PROT protein sequence database under accession number [P40559](P40559). Protein sequences were aligned using the Megalign program (DNAStar, Madison, WI). Identical amino residues are boxed, and hyphens indicate gaps introduced to maximize alignment. Asterisks indicate conserved motifs GDXN(Y/F)R and P(S/ A)W(C/T)DRIL that define inositol 5-phosphatases ([@B34]). Sop2 is 31% identical with synaptojanin along its full length.
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